SCHEMBL3377438

SCHEMBL3377438

O=C(c1cccc(N(Cc2ccccc2)S(=O)(=O)c2ccccc2)c1)N1CCC(Oc2ccccc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.54
KMT2A Q03164 3/20 0.53
HPGD P15428 1/20 0.53
ALDH1A1 P00352 1/20 0.51
MAPT P10636 2/20 0.47
PKM P14618 1/20 0.47
MEN1 O00255 1/20 0.46
F10 P00742 1/20 0.46
NR3C1 P04150 1/20 0.46
HRH1 P35367 1/20 0.46
CCR3 P51677 1/20 0.46
HTT P42858 1/20 0.45
PTGES O14684 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3377001 0.90 F10 (0.56) LMNAKMT2AHPGDALDH1A1F10
SCHEMBL303313 0.85 LMNA (0.57) LMNAKMT2AHPGDALDH1A1PKM
SCHEMBL3377152 0.82 LMNA (0.60) LMNAKMT2AHPGDALDH1A1PKM
SCHEMBL13065011 0.80 LMNA (0.55) LMNAKMT2AHPGDALDH1A1PKM
SCHEMBL302677 0.80 F10 (0.47) LMNAKMT2AHPGDALDH1A1F10
SCHEMBL3377977 0.79 LMNA (0.52) LMNAKMT2AHPGDALDH1A1PKM
SCHEMBL303740 0.79 LMNA (0.47) LMNAKMT2AHPGDALDH1A1PKM
SCHEMBL13064516 0.79 LMNA (0.60) LMNAKMT2AHPGDALDH1A1PKM
SCHEMBL13065202 0.78 CNR2 (0.60) LMNAKMT2AHPGDALDH1A1PKM
SCHEMBL12017289 0.78 GAA (0.55) LMNAKMT2AHPGDALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP claimed
US-9073834-B2 Potassium channel blockers XENTION LIMITED (GB) 2015-07-07 US claimed
US-20140221337-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2014-08-07 US claimed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP disclosed
US-9447033-B2 Potassium channel blockers JAPAN TOBACCO INC. (JP) 2016-09-20 US disclosed
US-20150259282-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2015-09-17 US disclosed
US-9073834-B2 Potassium channel blockers XENTION LIMITED (GB) 2015-07-07 US disclosed
US-20140221337-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2014-08-07 US disclosed
US-8673901-B2 Potassium channel blockers XENTION LIMITED (GB) 2014-03-18 US disclosed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221337-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 LMNA 1619/4885KMT2A 386/4885HPGD 3708/4885
US-20100087428-A1 Novel Potassium Channel Blockers HCN4, SCN2B, KCNH2 LMNA 2145/4885KMT2A 1511/4885HPGD 3196/4885
US-20150259282-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 LMNA 1619/4885KMT2A 386/4885HPGD 3708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.